Effects of cimetidine on jejunostomy effluents in patients with severe short-bowel syndrome

Scand J Gastroenterol. 1986 Sep;21(7):824-8. doi: 10.3109/00365528609011125.

Abstract

The effect of the H2-receptor blocking agent cimetidine on jejunal effluent was examined in eight short-bowel patients with high-output jejunostomies. Stool mass and faecal excretion of sodium and potassium were significantly reduced by intravenous injection of 400 mg cimetidine four times a day. The amount of calcium, magnesium, phosphate, zinc, and fat in jejunostomy effluent did not change significantly. Cimetidine may be considered an antidiarrhoeal drug in extensively small-bowel-resected patients with a jejunostomy and may reduce the need for parenteral saline supply in these patients.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cimetidine / therapeutic use*
  • Clinical Trials as Topic
  • Female
  • Humans
  • Injections, Intravenous
  • Intestinal Absorption / drug effects*
  • Jejunum / surgery
  • Lipid Metabolism
  • Malabsorption Syndromes / drug therapy*
  • Male
  • Middle Aged
  • Parenteral Nutrition
  • Short Bowel Syndrome / drug therapy*
  • Short Bowel Syndrome / therapy
  • Water-Electrolyte Balance / drug effects*

Substances

  • Cimetidine